Home / Diabetes In Control (page 724)

Diabetes In Control

Letter from the Editor: New Healthcare Rules

Some new healthcare rules took effect last week offering a measure of safety and security for our diabetes patients. As part of the healthcare reform act of 2010, adult children can stay on their parents’ insurance through age 26, they cannot be dropped for pre-existing conditions and their insurance cannot …

Read More »

Oral Medications and Diabetes

Oral_Medication

Oral Medications and Diabetes Nipro Diagnostics’ TRUEinsight® guide for patients focuses on understanding oral diabetes medications and how they help to control blood glucose levels. Understanding how oral medications work and their importance can help with patient medication compliance.

Read More »

New Product: Tiniboy Lancets (36 gauge/70mm)

TiniBoy_Lancet

Tiniboy Lancets (36 gauge/70mm) At 36 gauge and just 70mm in length, the Tinyboy lancet is the thinnest and shortest diabetic lancet. Dr. Stanley Kim developed the lancet. Dr. Kim — who has diabetes — wanted a lancet that would be less painful. He currently markets the Tinyboy lancet through …

Read More »

Immune System Genes Contribute to Type 1 Diabetes

Immune System Genes Contribute to Type 1 Diabetes: A new study found a link between immune system genes and the risk of Type 1 diabetes. Using a genome-wide association study, the researchers found that a certain group of genes that react in response to viral infections were present in both …

Read More »

Use of Diabetes Pills Up, Insulin Use Down

Use of Diabetes Pills Up, Insulin Use Down: The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60% in 1997 to 77% in 2007, a 28% increase, according to the latest “News and Numbers” from the Agency for Healthcare Research and …

Read More »

Once-weekly Exenatide vs. Sitagliptin or Pioglitazone

Once-weekly Exenatide vs. Sitagliptin or Pioglitazone: Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did. After 26 weeks, exenatide lowered the mean HbA1c level significantly more than either sitagliptin or pioglitazone (–1.5% vs. –0.9% and –1.2%). Patients who received exenatide also lost significantly more weight than …

Read More »